Lynparza more than doubled the time without
30 September 2019 15:30 BST Lynparza more than doubled the time without radiographic disease progression in patients with BRCA1/2- or ATM-mutated metastatic castration-resistant prostate cancer AstraZeneca and MSD's Lynparza reduced the risk of disease progression or death by 51% in men with homologous recombination repair (HRR) gene mutations First positive Phase III trial testing a targeted treatmentin biomarker-selected prostate cancer patients AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today presented